Large Inflow of Money Witnessed in Novavax

Novavax (NVAX) stock had a bullish inflow of $2.23 million worth of trades on uptick and an outflow of $1.09 million in downticks on Thursday. The total uptick to downtick ratio stood at 2.04. The net money flow into the stock was $1.14 million. The money flow data, which is calculated as the dollar value of composite uptick minus the downtick trades indicated bullish. The block trades had a total money flow of $0.46 million. $0.46 million of block trade during Uptick was observed, which shows continued buying by the smart money on every weakness. However, Novavax (NVAX) stock traded down $0.06 , and reached $7.41, a drop of -0.74% over the previous day. On a weekly basis, the stock is -1.13%, over the previous weeks close.


Novavax (NVAX) : The consensus price target for Novavax (NVAX) is $13.15 for the short term with a standard deviation of $3.81. The most optimist securities analyst among the 6 who monitor the stock believes that the stock can reach $17, however, the pessimist price target for the company is $6. The stock has recorded a 20-day Moving Average of 9.31% and the 50-Day Moving Average is 26.03%.

Novavax (NASDAQ:NVAX): The stock was completely flat for the day, closing at $7.46 on Thursday. The flat closing masks the intraday volatility in the stock. After opening at $7.49, the stock touched an intraday high of $7.65 and a low of $7.33. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $7.46. The total trading volume on Thursday was 3,695,006.

Novavax, Inc. (Novavax) is a clinical-stage vaccine company engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. The Companys product pipeline focuses on a variety of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Companys lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. The Company is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. The Company is developing additional pre-clinical stage programs in a variety of infectious diseases, including Middle East respiratory syndrome (MERS).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *